In recent years, the use of biomarkers in the ICU has surged. Biomarker research across medical fields has seen significant growth since the 1980s, aided by technological advancements. However, progress in critical care has been slower due to the complex and heterogeneous nature of critical illnesses.
Accurate biomarkers for diagnosis, prediction, and prognosis would greatly enhance our understanding of these conditions. Exciting advancements in point-of-care testing technologies offer potential for transforming biomarker application at the bedside, enabling diagnosis, risk stratification, molecular phenotyping, and monitoring treatment response. Biomarker panels, rather than single analytes, are being increasingly used to decrease costs. It is important to combine biomarkers with physician expertise and clinical judgment. Newer omic markers like transcriptomics, metabolomics, and genomics hold promise for personalized medicine. Validated biomarkers will enable accurate prediction, diagnosis, targeted treatments, and define treatment duration and short-term outcomes.
Analyzing large ICU datasets using AI can identify risk factors, prognosis, and outcomes for critically ill patients.
Key topics we would like to cover in this collection include: early diagnosis, risk assessment, treatment response, biological feasibility, ease of measurement, rapid results, and cost-benefit analysis.